The University of Bristol led a breakthrough study that determined new diabetic kidney disease (DKD) therapeutic targets. According to a release, they “could see patients treated with new gene and drug therapies preventing the disease’s progression into end stage kidney failure.”
The study involved scientists from the UK, Europe and US. Researchers “discovered specific cell changes in the kidney caused by insulin resistance.”
The team expanded on their previous work and “examined the changes caused by insulin-resistance in four types of kidney cells and then compared these changes with kidney biopsies from patients with early and late diabetic kidney disease.”
They found “multiple ‘common’ and ‘cell specific’ changes caused by insulin-resistance representing new targets for pharmacological or targeted gene therapy approaches.”
